The role of ADAMTS-13 and von Willebrand factor in venous thromboembolism.

静脉血栓栓塞是一种严重的循环系统疾病，由深静脉血栓阻塞肺动脉而发展。一些临床研究显示抗血小板药物在预防静脉血栓栓塞中的作用。然而，血小板和静脉血栓的累及尚不清楚。本研究对血小板功能表达重要的血管性血友病因子（VWF）及其控制蛋白进行了研究。深静脉血栓免疫组化研究显示静脉血栓纤维蛋白、血小板、VWF和因子VIII阳性。抗fviii抗体（中和抗体）降低了流室系统的血小板聚集，而抗vwf抗体和抗adamts -13抗体对血小板聚集没有抑制作用。在家兔静脉血栓模型中，FVIII可促进静脉血栓大小，增加血小板和纤维蛋白阳性面积。

Venous thromboembolism is a severe circulatory disorder that develops by occlusion of the pulmonary artery via deep venous thrombosis. The efficacy of anti-platelet agents is shown in the prevention of venous thromboembolism in some clinical studies. However, involvement of platelet and venous thrombosis is not clear. The present study investigates the von Willebrand factor (VWF), which is important to functional expression of platelet, and their control protein. Immunohistochemical study of deep venous thrombosis shows that venous thrombi is positive for fibrin, platelet, VWF and Factor VIII. Anti-FVIII antibody (Neutralizing antibody) reduced the platelet aggregation on flow chamber system, but not Anti-VWF antibody or Anti-ADAMTS-13.In rabbit venous thrombosis model, FVIII promoted the venous thrombus size, and increased the positive area of the platelet and fibrin.